Physician profile
Patrick Michael
NPI 1235426263
$521.38
in general payments reported to CMS, 2019-2025
15 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.92 · 2020: $14.98 · 2022: $45.62 · 2023: $17.04 · 2024: $97.62 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $431.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $81.86 | 2025 | |
| Lilly USA, LLC | $80.26 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $78.28 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $37.56 | 2025 | Shingrix, Arexvy |
| Amgen INC. | $36.99 | 2025 | Repatha, Evenity |
| Medtronic, INC. | $30.19 | 2022 | |
| Pfizer INC. | $29.24 | 2019-2025 | |
| Dynavax Technologies Corporation | $28.97 | 2024-2025 | Heplisav-B |
| Abiomed | $23.84 | 2025 | |
| Biotronik Nro, INC. | $20.39 | 2024 | Prospera |
| Janssen Pharmaceuticals, INC | $16.63 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $14.98 | 2020 | |
| Celgene Corporation | $14.96 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.16 | 2025 | Austedo Xr |
| Astrazeneca Pharmaceuticals Lp | $13.07 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.